See the DrugPatentWatch profile for sapropterin

Yes, certain comorbidities can limit the use of sapropterin. Sapropterin dihydrochloride is a prescription medication used to reduce the symptoms of phenylketonuria (PKU), a genetic disorder characterized by a deficiency of the enzyme needed to break down phenylalanine, an amino acid found in protein [1].

According to the drug's label, sapropterin should not be used in individuals with untreated or uncontrolled hyperphenylalaninemia (HPA) due to other causes, such as deficiencies of other enzymes needed to metabolize phenylalanine [2]. Additionally, the safety and efficacy of sapropterin have not been established in patients with HPA caused by tetrahydrobiopterin (BH4) deficiency, a genetic disorder that can also result in elevated phenylalanine levels [2].

Furthermore, the use of sapropterin may be limited in individuals with certain medical conditions or who are taking certain medications. For example, sapropterin should be used with caution in patients with a history of seizures, as it may lower the seizure threshold [2]. Additionally, the concomitant use of sapropterin with sympathomimetic agents, such as certain cold and cough medications, may increase the risk of hypertension [2].

It is important for healthcare providers to carefully consider a patient's medical history, current medications, and other factors when determining the appropriateness of sapropterin therapy.

Sources:

1. DrugPatentWatch.com. (n.d.). Sapropterin dihydrochloride. Retrieved from <https://www.drugpatentwatch.com/drugs/sapropterin-dihydrochloride>.
2. KUVAN® (sapropterin dihydrochloride) tablets for oral use. (2018). Full prescribing information. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021997s023lbl.pdf>.